A Randomized Open-Label Study of the Impact of Quetiapine Versus Risperidone on Sexual Functioning

Journal of Clinical Psychopharmacology

Volumn 24, Issue 1, 2004, Pages 56-61

  Knegtering, Rikus ^a   Castelein, Stynke ^a   Bous, Han ^a   Van Der Linde, Just ^b   Bruggeman, Richard ^a   Kluiter, Herman ^a   Van Den Bosch, Robert J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Adhesie Foundation for Mental Health Care Midden Overijssel   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CLOZAPINE; HYPOPHYSIS HORMONE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE;

ADULT; AMENORRHEA; ANORGASMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FEMALE; HUMAN; INTERVIEW; LIBIDO DISORDER; MALE; OLIGOMENORRHEA; OPEN STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL;

ADOLESCENT; ADULT; DIBENZOTHIAZEPINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PROLACTIN; PSYCHOTIC DISORDERS; QUESTIONNAIRES; RISPERIDONE; SCHIZOPHRENIA; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TESTOSTERONE; TREATMENT OUTCOME;

EID: 0942277248     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000106220.36344.04     Document Type: Article

References (46)

1. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, et al. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry. 1995;56:137-141.
2. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactí nemía. Schizophr Res. 1999;35:S75-S86.
3. Peuskens J, Sienarert P, De Hert M. Sexual dysfunction and anti-psychotics. Eur Psychiatry. 1998;13(suppl):23s-30s.
4. Dickson RA, Seeman MV, Corenblum B. Hormonal side effects in women: typical versus atypical antipsychotic treatment. J Clin Psychiatry. 2000;61(suppl 3):10-15.
5. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis. 1982;170:463-467.
6. Segraves RT. Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatty. 1989;46:275-284.
7. Sullivan G, Lukoff D. Sexual side effects of antipsychotic medication: evaluation and interventions. Hosp Community Psychiatry. 1990;41: 1238-1242.
8. Riley AJ, Riley EJ. Evaluation of drug effects on human sexual dysfunction In: Riley AJ, Peet M, Wilson C, eds. Sexual Pharmacology. Oxford: Clarendon Press; 1993;114-129.
9. Knegtering H, Moolen vd AEGM, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003;28(suppl 2):109-123.
10. Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry. 2002; 181:49-55.
11. Meston CM, Frohlich PF. The neurobiology of sexual functioning. Arch Gen Psychiatry. 2000;57:1012-1030.
12. Alexiadis M, Whithom D, Woodley H, et al. Prolactin elevation with Quetiapine. Am J Psychiatry. 2002;159:1608-1609.
13. Kaneda Y. Effects of risperidone on gonadal axis hormones in schizophrenia. Ann Pharmacother. 2001;35(12):1523-1527.
14. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158(3):360-369.
15. Kapur S, Roy P, Daskalakis J, et al. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry. 2001;158(2):311-314.
16. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57(6):553-559.
17. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155(7):921-928.
18. Kotin J, Wilbert DE, Verburg D, et al. Thioridazine and sexual dysfunction. Am J Psychiatry. 1976;133(1):82-85.
19. Aizenberg D, Modai I, Landa A, et al. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry. 2001;62(7):541-544.
20. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997;42: 233-246.
21. Borison RL, Arvantis LA, Miller BG, et al. ICI 204,636 an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacology. 2002; 16:158-169.
22. Dev V, Raniwalla J. Quetiapine: a review of its safety in the management of schizophrenia. Drug Safety. 2001;23:295-307.
23. Small JG, Hirsch SR, Arvanitis LA. Quetiapine in patients with schizophrenia. A high- and low-dose double blind comparison with placebo. Arch Gen Psychiatry. 1997;54:549-557.
24. Claus A, Bollen J, deCuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study. Acta Psychiatr Scand. 1992;85:295-305.
25. Knegtering H, Lamberts PA, Prakken G, et al. Serum prolactin levels and sexual dysfunction in antipsychotic medication, such as risperidone: a review. Acta Neuropsychiatr. 2000;12:19-26.
26. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross sectional study of side effects in psychotic patients. Acta Psychiatr Scand. 1987;334(suppl):1s-100s.
27. Bous J, Castelein S, Kluiter H, et al. The antipsychotics and sexual functioning questionnaire (ASFQ): a pilot study evaluating reliability and validity in patients treated with antipsychotics. Schizophr Res. 2003;60(1 special issue):353.
28. Dickson RA, Glazer WM, Violato C. A computerized self-report questionnaire for assessing sexual functioning in psychotic patients: the DGSF. Schizophr Res. 2001;49:283.
29. Kay SR, Fiszbein A, Poler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
30. Knegtering H, Castelein S, Linde van der J, et al. Sexual dysfunctions and antipsychotics. Schizophr Res. 2002;53(3):167.
31. Teusch L, Scherbaum N, Bohme H, et al. Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addicts. Pharmacopsychiatry. 1995;28:84-92.
32. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999; 156(2):286-293.
33. Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychol Med. 1992;22:305-327.
34. Schwartz MF, Bauman JE, Masters WH. Hyperprolactinemia and sexual disorders in men. Biol Psychiatry. 1982;17:861-876.
35. Caranai C, Granata AR, Fustini MF, et al. Prolactin and testosterone: their role in male sexual function. J Androl. 1996;19:48-54.
36. Rinieris P, Hatzimanolis J, Markianos M, et al. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients. Neuropsychobiology. 1989;22:146-149.
37. Sobrinho LG. The psychogenic effects of prolactin. Acta Endocrinol. 1993;129:38-40.
38. Exton NG, Truong TC, Exton MS, et al. Neuroendocrine response to film-induced sexual arousal in men and women. Psychoneuroendocrinology. 2000;25(2):187-199.
39. Haake P, Exton MS, Haverkamp J, et al. Absence of orgasm-induced prolactin secretion in a healthy multi-orgasmic male subject. Int J Impot Res. 2002;14(2):133-135.
40. Leysen JE, Janssen PMF, Heylen L, et al. Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects. Int J Psychiatry Clin Pract. 2000;2:53-517.
41. Shiloh R, Nutt D, Weizman A. Ejaculation: supposed mechanism and various agents that can affect retrograde ejaculation. Atlas of Psychiatric Pharmacotherapy. London: Martin Dunitz; 1999;86-89.
42. Girgis T. Aspermia, a survey of forty-nine cases. Fertil Steril. 1968; 19:580-588.
43. Shader RI, Elkins R. The effects of antianxiety and antipsychotic drugs on sexual behavior. Mod Probl Pharmacopsychiatry. 1980;15:91-110.
44. Finn SE, Baily JM, Schultz RT, et al. Subjective utility ratings of neuroleptics in treating schizophrenia. Psychol Med. 1990;35:843-848.
45. Singh SP, Beck AJ. No sex please, we're British. Psychiatr Bull. 1997; 21:99-101.
46. Halbreich U, Kinon BJ, Gilmore JAS, et al. Evaluated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 2003;28(suppl):53-67.